• 1
    Buéno L, Fioramonti J, Rukebusch Y, Frexinos J, Coulon P. Evaluation of colonic myoelectric activity in health and in functional disorders. Gut 1985; 21: 4805.
  • 2
    Frexinos J, Fioramonti J, Buéno L. Colonic myoelectrical activity in IBS painless diarrhoea. Gut 1987; 28: 161318.
  • 3
    Whitehead WE, Engle BJ, Schuster MM. Irritable bowel syndrome: physiological and psychological difference between diarrhoea-predominant and constipation-predominant patients. Dig Dig Sci 1980; 35: 40413.
  • 4
    Welgan P, Meshkinpour H, Beeler M. Effect of anger on colon motor and myoelectric activity in the irritable bowel syndrome. Gastroenterology 1988; 14: 11506.
  • 5
    Camilleri M, Neri M. Motility disorders and stress. Dig Dis Sci 1989; 34: 177786.
  • 6
    Sullivan MA, Cohen S, Snape WJ Jr. Colonic myoelectrical activity in irritable bowel syndrome. Effect of eating and anticholinergics. N Engl J Med 1978; 298: 87883.
  • 7
    Bazzochi G, Ellis J, Villanueva-Meyer J, et al. Postprandial colonic transit and motor activity in chronic constipation. Gastroenterology 1990; 98: 68693.
  • 8
    Snape WJ Jr. Irritable bowel syndrome. In: Cohen S, Soloway RD, eds. Functional Disorders of the Gastrointestinal Tract. New York: Churchill Livingstone, 1987: 69–83.
  • 9
    Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973; 14: 12532.
  • 10
    Swarbrick ET, Bat L, Hegorty JE, Williams CB. Site of pain from the irritable bowel. Lancet 1980; ii: 4436.
  • 11
    Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distension in irritable bowel syndrome. Gastroenterology 1990; 98: 118792.
  • 12
    Ritchie J. Mechanisms of pain in irritable bowel syndrome. In: Read, NW, ed. Irritable Bowel Syndrome. Philadelphia: Grune and Stratton, 1985: 163–172.
  • 13
    Dawson AM. Origin of pain in the irritable bowel syndrome. In: Read, NW, ed. Irritable Bowel Syndrome. Philadelphia: Grune and Stratton, 1985: 155–162.
  • 14
    Bradette M, Delvaux M, Staumont G, Fioramonti J, Buéno L, Frexinos J. Evaluation of colonic sensory thresholds in IBS patients using a barostat: definition of optimal conditions and comparison with healthy subjects. Dig Dis Sci 1994; 39: 44957.
  • 15
    Lasser RB, Bond JH, Levitt MD. The role of intestinal gas in functional abdominal pain. N Engl J Med 1975; 293: 5246.
  • 16
    Mayer EA, Gebhart GF. Functional bowel disorders and the visceral hyperalgesia hypothesis. In: Mayer EA, Raybould HE, eds. Basic and Clinical Aspects of Chronic Abdominal Pain. New York: Elsevier, 1993: 3–28.
  • 17
    Camilleri M, Von Der Ohe MR. Drugs affecting serotonin receptors. Bailliére’s Clin Gastroenterol 1994; 8: 30119.
  • 18
    Prior A, Read NW. Reduction of rectal sensitivity and postprandial motility by granisetron, a 5-HT3 receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 17580.
  • 19
    Hammer J, Phillips SF, Talley NJ, Camilleri M. Effect of a 5-HT3 antagonist (ondansetron) on rectal contractility and compliance in health and the irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 54351.
  • 20
    Goldberg PA, Kamm MA, Setti-Carraro P, et al. 5-HT3 antagonism does not modify visceral sensation or compliance in healthy subjects. Gastroenterology 1993; 104: A512 (Abstract).
  • 21
    Clayton NM, Gale JD, Bountra C, Forster ER. Normalisation of perturbed small bowel transit by alosetron, a 5-HT3 receptor antagonist in the rat. Dig Dis Sci 1996; 41: 1903 (A95).
  • 22
    Scott CM, Green A, Gale JD, Bunce KT. The effect of 5-HT3 receptor antagonists on the depressor effect of colorectal distension in the anaesthetised rat. Br J Pharmacol 1994; 112: 101P.
  • 23
    Bardhan K, Bodemar G, Geldof H, Schutz E, Snell C, Darekar B. A double-blind placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Gastroenterology 1996; 110: A630 (Abstract).
  • 24
    Thompson WS, Dotterval G, Drossman DA, Heaton KW, Kruis SW. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int 1989; 2: 925.
  • 25
    Hatchet T, Caussette M. A multifunction and programmable computerised barostat. Gastroenterol Clin Biol 1993; 17: 34751.
  • 26
    Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 4052.
  • 27
    Delvaux M, Louvel D, Scherre B, Fraitag B, Frexinos J. The k-agonist Fedotozine increases thresholds of first sensation and pain perception to colonic distension in patients with Irritable Bowel Syndrome. Gastroenterology 1995; 108: A590 (Abstract).
  • 28
    Von Der Ohe MR, Camilleri M, Kvols LK. A 5-HT3 antagonist corrects the post-prandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology 1994; 106: 11849.
  • 29
    Von Der Ohe MR, Hanson RB, Camilleri M. Serotonergic mediation of post-prandial colonic tonic and phasic responses in man. Gut 1994; 35: 53641.
  • 30
    Lagier E, Delvaux M, Mètivier S, et al. Colonic tone influences thresholds of sensory perception to luminal distension in IBS patients. Gastroenterology 1996; 110: A700 (Abstract).
  • 31
    Distrutti E, Azpiroz F, Soldevilla A, Malagelada JR. Perception of rectal distension depends on wall tension, but not on expansion. Gastroenterology 1996; 110: A657 (Abstract).
  • 32
    Banner SE, Sanger GJ. The effect of 5HT3 receptor antagonists on visceral pseudoaffective reflexes. Paper presented at Serotonin 1991. 5-hydroxytryptamine-CNS receptors and brain function, Birminghan, UK, 1991: 78 (Abstract).
  • 33
    Morteau O, Eeckhout C, Buéno L. Effect of the 5-HT3 antagonists in visceromotor and nociceptive responses to rectal distension before and during experimental colitis in rats. Fundam Clin Pharmacol 1994; 8: 55362.